Skip to content


2minút, 25sekúnd
Title: European Research and Preparedness Network for Pandemics and Emerging Infectious Diseases
Project Number: 101015736
Call identifier: H2020-IBA-SC1-CORONAVIRUS-2020-3
Program: H2020
Funding Scheme: RIA – Research and Innovation action
Coordinator: National Institute of Health and Medical Research, France
Address of Coordinator: France
UPJS contact:
Consortium members: Pavol Jozef Šafárik University in Košice
  European Clinical Research Infrastructure Network (ECRIN), France
  Folkehelseinstituttet, Norway
  Oslo University Hospital HF, Norway
  University of Verona, Italy
  University Hospital Center of São João EPE, Portugal
  Inserm Transfert, SA, France
  Université libre de Bruxelles, Belgium
  University of Szeged, Hungary
  University College Cork – National University of Ireland, CORK, Ireland
  Swiss Clinical Trial Organisation, Switzerland
  Hacettepe University, Turkey
  Centre Hospitalier de Luxembourg, Luxembourg
  Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH, Austria
  Assistance Publique–Hôpitaux de Paris, France
  Université Hospital of Lyon, France
  Servicio Madrileño de Salud, Spain
  National and Kapodistrian University of Athens, Greece
  Medical University of Lodz, Poland
  Charles University, Czechia
Start Date: 1 July 2020
End Date: 30 June 2025
Objective: The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and expertise, allowing European expansion of DisCoVeRy (WP1) and the establishment of a COVID19 adaptive platform trial (WP2). The DisCoVeRy trial, designed as a multi-arm adaptive repurposing trial, initiated in France, has the potential to expand to many other European countries with appropriate support in terms of multinational funding and trial management capacity. This will complete the evaluation of repurposed drugs, while building a European clinical trial network which, together with other European networks such as the Solidarity trial, will design and run a new European platform trial. EU-RESPONSE will swiftly generate robust evidence for drug repurposing or registration, through a modular trial framework allowing most European hospitals to participate at their preferred level of commitment, thus building a network of investigation sites within European and associated countries. Cooperation with other European platforms, in particular the RECOVER consortium platform will be achieved through a joint coordination mechanism aligned with European and national policies (WP3), ensuring a coordinated strategy for the European COVID-19 Adaptive Platform Trials, their complementarity in providing access for requests for a new domain or arm, their synergy and cross-fertilization through the development of a common toolbox for the development and the management of Adaptive Platform Trials. Joining forces in Europe and with international partners, it will contribute to the global clinical trial capacity for urgently meeting the expectations of society and developers. It will also boost multinational cooperation in Europe and promote the establishment of adaptive platform trials in other diseases, and will have a major impact on epidemic control.
Related links:

Study at UPJŠ